Key Unmet Needs Associated with Idiopathic and Progressive Pulmonary Fibrosis

Opinion
Video

Dr. Frohna covers unmet needs in the latest treatment guidelines and therapies used to combat idiopathic and progressive pulmonary fibrosis.

  1. What were the key updates for treatment in the 2022 ATS Guidelines and what additional information is needed in future iterations?
    1. How do you see the guidelines changing as novel agents enter the treatment landscape?
  2. There were no FDA-approved therapies for IPF/PPF prior to anti-fibrotic agents. How have these therapy options altered treatment of the disease?
Recent Videos
1 Kol is featured in this series
1 Kol is featured in this series
1 Kol is featured in this series
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 Kol is featured in this series
1 KOL is featured in this series.
1 KOL is featured in this series.
1 Kol is featured in this series
Related Content
© 2024 MJH Life Sciences

All rights reserved.